Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics company Ischemia Care has developed a laboratory-developed test, the ISCDx, that it says can better determine the cause of strokes based on gene expression analysis, and help clinicians better treat patients.

The Oxford, Ohio-based firm is using a microarray-based platform leveraging technology licensed from the University of California to diagnose different types of stroke from blood samples, including ischemic strokes and transient strokes whose symptoms quickly abate.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.